Home Cart Sign in  
Chemical Structure| 95510-70-6 Chemical Structure| 95510-70-6

Structure of Omeprazole sodium
CAS No.: 95510-70-6

Chemical Structure| 95510-70-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Omeprazole sodium is a proton pump inhibitor (PPI) with potential in gastrointestinal disease research. It competitively inhibits the activity of CYP2C19. Additionally, omeprazole can inhibit the growth of both Gram-positive and Gram-negative bacteria. It is also an inhibitor of neutral sphingomyelinase (N-SMase), which has exosome-inhibiting effects.

Synonyms: H 16868 sodium

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Omeprazole sodium

CAS No. :95510-70-6
Formula : C17H18N3NaO3S
M.W : 367.40
SMILES Code : O=S(C1=NC2=CC=C(OC)C=C2[N-]1)CC3=NC=C(C)C(OC)=C3C.[Na+]
Synonyms :
H 16868 sodium
MDL No. :MFCD07802816

Safety of Omeprazole sodium

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H315-H318-H335-H410
Precautionary Statements:P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P310-P330-P362+P364-P403+P233-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Description
Omeprazole sodium (H 16868 sodium), another form of this proton pump inhibitor, also targets acid-related gastrointestinal disorders and similarly inhibits CYP2C19 activity with a Ki of 2 to 6 μM[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
Human peripheral blood mononuclear cells (PBMC) 50 μg/mL 4 and 24 hours Evaluate the inhibitory effect of omeprazole on LPS-induced inflammatory cytokine production, results showed omeprazole inhibited TNF-α, MCP-1, IL-23, and IL-12 production PMC8787384
THP-1 cell-derived macrophages 50 μg/mL 4 hours Evaluate the inhibitory effect of omeprazole on TLR4 signaling pathways, results showed omeprazole significantly inhibited NF-κB/AP-1 and IRF activation PMC8787384
Mouse fundic organ cultures 80 μmol/ml 12 hours To investigate the effect of Ca2+i chelation on Shh gene expression, results showed that EGTA and BAPTA-AM significantly inhibited Shh expression. PMC2997213
Human saphenous vein segments (SV) 3 to 100 μM 24 hours To study the effect of omeprazole on NO production, results showed that omeprazole significantly inhibited NOx release. PMC3838201
Human microvascular endothelial cells (HMVECs) 20 μM 24 hours To study the effect of PPIs on ADMA concentration in endothelial cells, results showed that PPIs increased intracellular ADMA by ~30%. PMC3838201
RAW264.7 macrophages 50 µM 72 hours Test the protective effect of omeprazole on Mycobacterium tuberculosis-infected macrophages, results showed omeprazole failed to protect macrophages at 50 µM PMC4510652
MRC-5 lung fibroblasts 50 µM 72 hours Test the protective effect of omeprazole against Mycobacterium tuberculosis-induced cytotoxicity, results showed omeprazole failed to protect fibroblasts at 50 µM PMC4510652

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Men1ΔIEC; Sst−/− mice Oral 200 ppm chow 6 months to 1 year To study the effect of omeprazole on gastrin expression and menin nuclear export in Men1ΔIEC; Sst?/? mice, results showed omeprazole treatment increased gastrin expression and menin nuclear export. PMC5705278
Mice Wild-type mice Intraperitoneal injection 400 μmol/kg Once daily for 3 consecutive days To investigate the effect of omeprazole on gastric acid secretion and Shh gene expression, results showed that omeprazole significantly inhibited gastric acid secretion and Shh gene expression. PMC2997213
Mice Wild-type C57BL/6 mice Intraperitoneal injection 10 μmol/mouse Single injection, euthanized after 2 hours Omeprazole inhibited gastric acid secretion and reduced Shh expression, with additive effect when combined with IL-1β PMC2895809
Mice H. pylori infection model Oral gavage 1.5 mg/20 g body weight Once daily for one week To evaluate the effect of omeprazole on the distribution of H. pylori in the stomach. Results showed that omeprazole-mediated acid suppression promoted H. pylori colonization in the proximal and distal corpus but did not alter its distribution within the gastric glands. PMC6309511
Mice Men1ΔIEC; Sst−/− mouse model Dietary administration 200 ppm 6 months To investigate the effect of omeprazole on gastric carcinoid development. Results showed that omeprazole treatment accelerated gastric carcinoid formation in Men1ΔIEC; Sst?/? mice, associated with hypergastrinemia. PMC4980289
Mice Gastric mucosal injury model Intraperitoneal injection 60 mg/kg At least 30 minutes before surgery Omeprazole reduced maximal damage size and accelerated epithelial repair, although only at pH 3 did omeprazole further increase surface pH above the level caused by imposed damage. PMC3418063
Mice Acute esophagitis model Subcutaneous injection 400 μmol/kg Single dose administered 1 hour before surgery Omeprazole significantly reduced MPO activity and pathological damage scores in wild-type mice, similar to the effect of the VR-1 antagonist capsazepine. PMC1856385
C57BL/6 wild-type male mice LPS-induced acute lung injury (ALI) model Intratracheal injection 75 μg/kg Nano-OM Single dose, samples collected after 24 hours Evaluate the therapeutic effect of nano-omeprazole on ALI, results showed nano-omeprazole reduced inflammatory cell infiltration and cytokine production, protecting the lungs from injury PMC8787384
INS-GAS mice H. pylori infection model Oral 400 μmol/kg/d Twice daily for 7 days To evaluate the efficacy of omeprazole combined with antibiotics in preventing the progression of gastric cancer in H. pylori-infected mice. Results showed that early treatment (8 weeks) completely prevented the development of GIN, while treatments at 12 and 22 weeks also significantly reduced the severity of GIN. PMC2653414
Male C57BL/6JJcl mice High-fructose diet-induced small intestine injury model Intraperitoneal injection 20 mg/kg Once daily for 9 weeks Omeprazole exacerbated ASA-induced intestinal damage, significantly decreased Bifidobacteria levels, and significantly increased A. muciniphila counts in the jejunum. PMC7527075

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.72mL

0.54mL

0.27mL

13.61mL

2.72mL

1.36mL

27.22mL

5.44mL

2.72mL

References

 

Historical Records

Categories